---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056451"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:18:33.004299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M

## Summary
- Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.
- Cash, equivalents and marketable securities: $326.3M as of Sep 30, 2021; sufficient through end of 2023.
- R&D expenses increased to $24.3M (from $17.8M) driven by PC14586 clinical development.
- Phase 1/2 trial of p53 Y220C reactivator PC14586 data expected in first half 2022.
- Appointed Tim Smith as SVP, Head of Corporate Development.

## SEC filing metadata
- accession: 0001564590-21-056451
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/0001564590-21-056451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/pmvp-8k_20211112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056451
- JSON: https://secwatch.observer/filing/0001564590-21-056451.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.